StemCells grants license to StemCell Technologies to studyneural stem cells.
"We are very pleased that StemCell Technologies has agreed to take a license for supplying these materials to the research market," said Martin McGlynn, President and CEO of StemCells. "One of the benefits of our extensive patent portfolio is that we are in a position to encourage research on neural stem cells. I believe that this license will help researchers obtain legitimate access to murine stem cells and associated materials. As I have said before, the more we can learn about the ways in which neural stem cells can be used to improve human health, the more potential there is to use stem cells for therapeutic purposes."
"StemCell Technologies is delighted to receive this license from StemCells, Inc," said Dr. Allen Eaves, President and CEO of StemCell Technologies. "Neural stem cell research is an exciting area of study that holds tremendous promise. We firmly believe that our company can make a significant contribution in helping to move this field forward through the timely development and delivery of high quality standardized research tools, as we have done previously for the hematopoietic stem cell field."
StemCells is the owner or exclusive licensee of 38 issued United States patents of which the majority are in the neural stem cell field, as well as numerous issued and pending foreign counterparts. The license covers the research use of cells under ten of the United States patents and their foreign counterparts.
StemCells, Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury.
StemCell Technologies provides highly specialized cell culture media and cell separation products that support and enable medical research in areas such as cancer, hematology, immunology, cell transplantation, gene therapy, and developmental biology. StemCell Technologies' lead product, MethoCult, is the industry standard media for hematopoietic progenitor assays. The company also offers training courses, coordinates a global proficiency testing program for hematopoietic progenitor assays, and provides contract assay services to the biotechnology and pharmaceutical industry.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Sep 1, 2003|
|Previous Article:||Protein Design Labs and Genentech extend antibody agreement.|
|Next Article:||Repligen announces district court decision in inventorship dispute with Bristol-Myers Squibb.|